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Abstract
Introduction: The data on the coronavirus disease (COVID-19) in solid-organ transplant recipients (SOTRs) in Croatia is unknown. The aim of this 
study was to analyze the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Croatian SOTRs. 
Materials and methods: From 7 September to 27 November 2020 (beginning of the second COVID-19 pandemic wave), a cross-sectional screening 
for COVID-19 was performed in the adult outpatient liver (LTRs; N = 280) and kidney transplant recipients (KTRs; N = 232). Serum samples were ini-
tially tested for SARS-CoV-2 IgG antibodies using a commercial enzyme-linked immunosorbent assay (ELISA; Vircell Microbiologists, Granada, Spain). 
All positive samples were confirmed using a virus neutralization test (VNT). Data on risk exposure and COVID-19 related symptoms were collected 
using a questionnaire.
Results: The transplanted cohort’s seroprevalence detected by ELISA and VNT was 20.1% and 3.1%, respectively. Neutralizing (NT) antibodies de-
veloped in 15.6% of anti-SARS-CoV-2 ELISA IgG positive SOTRs. The difference in seropositivity rates between LTRs and KTRs was not statistically 
significant (ELISA 21.1% vs. 19.0%, P = 0.554; VNT 3.6% vs. 2.6%, P = 0.082). Overall VNT positivity rates were higher in patients who reported 
participation in large community events (5.9% vs. 1.0%; P = 0.027) as well as in patients who reported COVID-19 related symptoms in the past six 
months. In addition, symptomatic VNT positive patients showed significantly higher (P = 0.031) NT antibody titers (median 128, interquartile range 
(IQR) = 32-128) compared to asymptomatic patients (median 16, IQR = 16-48). 
Conclusions: This study showed that 15.6% of anti-SARS-CoV-2 ELISA positive Croatian SOTRs developed NT antibodies indicating protective immu-
nity. Further studies are needed to determine the dynamic of NT antibodies and COVID-19 immunity duration in immunocompromised populations 
such as LTRs and KTRs.
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Introduction
Patients after solid-organ transplantation have 
been severely affected by the coronavirus disease 
2019 (COVID-19) pandemic. Disruption of medical 
services, higher risk of infection, and its conse-
quences are major reasons for the concern in this 
immunocompromised group of patients. Immuno-
suppression modulates the immune system, affect-
ing humoral immune responses against various 
pathogens, including viruses. The serologic immu-
noglobulin G (IgG) response against severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) 
has been an intense investigation area; however, 
the immune response to SARS-CoV-2 after trans-
plantation remains unknown and directs further 
research. The screening with SARS-CoV-2 IgG en-
zyme-linked immunosorbent assay (ELISA) fol-
lowed by virus neutralization test (VNT) confirma-
tion is a reliable approach for seroepidemiological 
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studies, which is crucial to assess infection attack 
rates in the population and herd immunity (1). Cur-
rently, there is a lack of seroprevalence data for 
specific patient populations, such as transplanted 
patients. In Croatia, the first case of COVID-19 has 
been reported on 25 February 2020, affecting more 
than 334,229 people and resulting in 7130 deaths 
by 2 May 2021. During the first (February-May 2020) 
and second (August 2020-February 2021) pandem-
ic waves, cases have been recorded in all Croatian 
counties. However, there are few published studies 
on the prevalence of SARS-CoV-2 in selected popu-
lation groups and the COVID-19 seroprevalence in 
the solid-organ transplant recipients (SOTRs) is un-
known. In this study, we analyzed the seropreva-
lence of SARS-CoV-2 at the beginning of the sec-
ond pandemic wave in liver (LTRs) and kidney 
transplant recipients (KTRs) in Croatia.
Materials and methods
Subjects
We performed a cross-sectional screening for 
COVID-19 in 512 adult outpatient SOTRs in a single 
transplant center in Croatia: LTRs (N = 280) and 
KTRs (N = 232) from 7 September to 27 November 
2020, at the beginning of the second wave COV-
ID-19 epidemic curve in Croatia. All transplanted 
patients who had an appointment in the trans-
plant outpatient clinic in this period and signed 
the informed consent were included in the study. 
All patients were asymptomatic at the time of 
sampling. The study was approved by the Hospital 
Ethics Committee (reference: 03/1-7732/9). 
Methods
Each patient was submitted to a COVID-19 ques-
tionnaire regarding the risk exposure (attendance 
to large meetings such as weddings/funerals/con-
certs, traveling abroad or receiving blood prod-
ucts) and COVID-19 related symptoms (fever, 
cough, ageusia, anosmia, headache, and myalgia) 
since the beginning of 2020, as well as previous 
SARS-CoV-2 reverse transcription polymerase 
chain reaction (RT-PCR) testing. The questionnaire 
response rate was 82%. All participants were en-
rolled in the study, regardless of the response to 
questionnaire. Blood samples were collected by 
venipuncture in serum blood tubes (without anti-
coagulants) in a non-fasting state at any time of 
day. After centrifugation (3000 rpm for 10 min), se-
rum samples were stored at - 20 °C until testing.
All samples were initially screened for the pres-
ence of SARS-CoV-2 IgG antibodies. A commercial 
enzyme-linked immunosorbent assay (ELISA; COV-
ID-19 ELISA IgG, Vircell Microbiologists, Granada, 
Spain) was used to detect SARS-CoV-2 IgG anti-
bodies in human serum samples. The assay is 
based on recombinant spike glycoprotein (S) and 
nucleocapsid protein (N) antigens of SARS-CoV-2. 
The results were calculated and expressed as anti-
body index [AI = (sample optical density (OD)/cut 
off serum mean OD)] x 10 and interpreted as fol-
lows: < 4 negative, 4-6 borderline, > 6 positive. 
Positive, negative, and cut-off controls have been 
run with each test run. Serologic tests were run on 
automated ELISA analyzer (VirClia, Vircell Microbi-
ologists, Granada, Spain). Initial ELISA validation 
was performed using serum samples from pa-
tients with RT-PCR confirmed COVID-19 (N = 15) 
collected 4-34 days after disease onset and asymp-
tomatic persons (N = 15) with negative RT-PCR and 
negative VNT (2). 
All ELISA reactive samples were confirmed using a 
VNT. The SARS-CoV-2 isolated in Vero E6 cells from 
the nasopharyngeal swab of a COVID-19 patient 
was used for the VNT. The maximum cytopathic 
effect was visible on the 4th day, and the virus rep-
lication was confirmed by RT-PCR. Virus titer 
(TCID50) was calculated using the Reed and 
Muench formula (3). Heat-inactivated serum sam-
ples (56 °C/30 min) were tested in duplicate in 96-
well plates. Two-fold serum dilutions starting from 
1:2 were prepared and mixed with the equal-vol-
ume (25 μL) suspension containing median tissue 
culture infectious dose (100 TCID50) of the virus. 
After 1 h of incubation (37 °C) in a CO2 incubator, a 
50 μL suspension of Vero E6 cells (final concentra-
tion: 2 x105 cells/mL) was added to each well and 
incubated for 4 days. To ensure optimal testing re-
sults, virus antigen used in each run was back ti-
trated and positive sample with known titer as 
well as negative control sample were included in 
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each plate. The antibody titer was defined as the 
highest serum dilution’s reciprocal value that 
showed 100% neutralization in at least half of the 
infected wells. Neutralizing (NT) antibody titers ≥ 8 
were considered positive (4). 
Statistical analysis
Statistical analysis was performed using SPSS Ver-
sion 17.0.1. (SPSS Inc, Chicago, IL, USA). Differences 
between the groups were tested using χ2 or Fish-
er’s exact test (categorical variables) and Mann-
Whitney U test (ordinal or numerical variables).The 
level of statistical significance was set at P < 0.05.
Results
The investigated cohort included 232 KTRs (medi-
an 53 years, 22-80; male 60.8%) and 280 LTRs (me-
dian 63 years, 22-83, male 72.5%). Out of 512 trans-
planted patients, 103 or 20.1% (95%CI = 16.4-26.3) 
were anti-SARS-CoV-2 IgG positive using ELISA (AI 
> 6). The difference in IgG seroprevalence be-
tween LTRs and KTRs was not statistically signifi-
cant (N = 59 or 21.1%; 95%CI = 16.4-26.3 vs. N = 44 
or 19.0%; 95%CI = 14.1-24.6, P = 0.554). Out of 103 
seropositive participants, only 20.4% reported pre-
vious nasopharyngeal (NP) swab RT-PCR testing, 
with 6/21 confirmed as SARS-CoV-2 positives. One 
anti-SARS-CoV-2 IgG negative patient reported a 
previous positive RT-PCR test. 
The overall prevalence of NT antibodies (titer ≥ 8) 
was 3.1% (95%CI = 1.8-5.0), with no statistically sig-
nificant difference (P = 0.536) between KTRs (2.6%; 
95%CI = 0.9-5.5) and LTRs (3.6%; 95%CI = 1.7-6.5). 
The prevalence of NT antibodies in ELISA positive 
patients was 16/103 (15.5%, 95%CI = 9.1-24.0).
Seroprevalence rates according to risk factors and 
clinical symptoms in KTRs and LTRs who responded 
to a questionnaire (N = 420) are presented in Tables 
1 and 2. There were no differences in the overall 
VNT positivity rate in SOTRs regarding received 
blood products (3.0%; 95%CI = 0.1-12.0 vs. 1.6%; 
95%CI = 0.6-3.4, P = 0.553) and travelling habits (5.3%; 
95%CI = 0.6-17.8 vs. 1.1%; 95%CI = 0.3-2.7, P = 0.085). 
However, a significant difference was found regard-
ing attendance to large group meetings (5.9%; 
95%CI = 0.7-19.7 vs. 1.0%; 95%CI = 0.3-2.6, P = 0.027).
Anti-SARS-CoV-2 IgG antibodies were found in 
both asymptomatic patients (N = 301) and patients 
who reported COVID-19 related symptoms in the 
past six months (N = 119). In the KTR group, signifi-
cantly higher VNT positivity rates were document-
ed in patients who reported fever, cough, anosmia 
and ageusia compared to patients who reported 
no symptoms (Table 1). In a LTR group, NT antibod-
ies were more frequently detected in patients who 
reported cough and breathing difficulties (Table 2).
Symptomatic patients had significantly higher (P = 
0.031) NT antibody titers (median 128, IQR = 32-
128) compared to asymptomatic patients (median 
16, IQR = 16-48) (Figure 1).
Figure 1. Anti-SARS-CoV-2 neutralizing antibody titers in symptomatic (N = 11, dark) and asymptomatic (N = 5, light) transplanted 
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N (%) tested
ELISA IgG positive VNT positive
N (%) 95%CI P N (%) 95%CI P
Risk factors
Blood transfusion




No 196 (94.7) 10 (5.6) 2.8-9.8 6 (3.1) 1.1-6.5
Participation in large 
community events




No 191 (92.3) 31 (16.2) 11.3-22.2 4 (2.1) 0.6-5.3
Travelling abroad




No 179 (86.5) 29 (16.2) 11.1-22.4 4 (2.2) 0.6-5.6
Clinical symptoms
Fever




No 177 (85.5) 26 (14.7) 9.8-20.8 1 (0.6) 0-3.1
Cough




No 186 (89.8) 29 (15.6) 10.7-21.6 1 (0.5) 0-2.9
Breathing difficulties




No 191 (92.3) 32 (16.7) 11.7-22.8 5 (2.6) 0.8-6.0
Anosmia




No 202 (97.6) 31 (15.3) 10.6-21.1 2 (1.0) 0.1-3.5
Ageusia




No 203 (98.1) 32 (15.8) 11.0 - 21.5 3 (1.5) 0.3-4.3
Headache




No 182 (87.9) 30 (16.5) 11.4-22.7 5 (2.7) 0.9-6.3
Muscle aches




No 192 (92.8) 31 (16.1) 7.8-55.1 4 (2.1) 0.5-5.3
*One-sided 97.5% confidence interval. ELISA - enzyme-linked immunosorbent assay. IgG - immunoglobulin G. VNT - virus 
neutralization test. P < 0.05 was considered statistically significant.
Table 1. COVID-19 seroprevalence in kidney transplant recipients according to potential risk factors and clinical symptoms (N = 207)
https://doi.org/10.11613/BM.2021.030901 Biochem Med (Zagreb) 2021;31(3):030901 
  9
Mrzljak A. et al. SARS-CoV-2 antibodies in Croatian transplant recipients 
N (%) 
tested
ELISA IgG positive VNT positive
N (%) 95%CI P N (%) 95%CI P
Risk factors
Blood transfusion




No 180 (84.5) 35 (19.4) 13.9-26.0 3 (1.1) 0.2-3.1
Participation in large 
community events




No 195 (91.5) 37 (19.0) 13.7-25.2 2 (1.0) 0.1-3.7
Travelling abroad




No 203 (95.3) 37 (18.2) 13.2-24.2 2 (1.0) 0.1-3.5
Clinical symptoms
Fever




No 179 (84.1) 30 (16.7) 11.6-23.1 2 (1.1) 0.1-4.0
Cough




No 194 (91.1) 39 (20.1) 14.7-26.4 2 (1.0) 0.1-3.7
Breathing difficulties




No 200 (93.9) 40 (0.2) 14.7-20.2 1 (0.5) 0-2.7
Anosmia
Yes 2 (0.9) 0 (0) 0-8.4*
0.534
0 (0) 0 - 84.1*
1.000
No 211 (99.1) 41 (19.4) 14.3-25.4 4 (1.9) 0.5 - 4.8
Ageusia




No 207 (97.2) 40 (19.3) 14.2-25.4 4 (1.9) 0.5-4.8
Headache




No 184 (86.4) 39 (21.2) 15.6-27.9 4 (2.2) 0.6-5.5
Muscle aches




No 188 (88.3) 37 (19.7) 14.3-26.2 3 (1.6) 0.3-4.6
*One-sided 97.5% confidence interval. ELISA - enzyme-linked immunosorbent assay. IgG - immunoglobulin G. VNT - virus 
neutralization test. P < 0.05 was considered statistically significant.
Table 2. COVID-19 seroprevalence in liver transplant recipients according to potential risk factors and clinical symptoms (N = 213)
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Discussion
This is the first study to demonstrate the anti-
SARS-CoV-2 seroprevalence in the Croatian LTRs 
and KTRs. The study was conducted at the begin-
ning of the second COVID-19 pandemic wave (Sep-
tember-November 2020), demonstrating the 
transplanted cohort’s seroprevalence of 20.1% us-
ing ELISA with 15.6% of anti-SARS-CoV-2 IgG posi-
tive SOTR who developed NT antibodies. The sero-
prevalence in this population group was found to 
be significantly higher compared to some other 
populations. At the end of the first wave, the SARS-
CoV-2 seroprevalence in Croatia was very low. Us-
ing immunochromatography assay, IgG antibodies 
were detected in only 1.27% of industry workers 
Split-Dalmatia and Šibenik-Knin County (5). Be-
sides, 2.7% of healthcare workers tested seroposi-
tive using ELISA, while NT antibodies were found 
in only 1.5% of the tested (4). Additionally, 2.2% of 
the general population were shown to be ELISA 
positive after the first wave, with low titers of NT 
antibodies detected in only 0.2% of individuals (6). 
A more recent study conducted among children 
from Children’s hospital Zagreb showed that the 
prevalence of anti-SARS-CoV-2 antibodies differed 
significantly between the first wave (2.9%) and the 
second wave (8.4%) of the COVID-19 pandemic (7).
The presentation of SOTRs with COVID-19 appears 
similar to the general population, and the majority 
develop symptoms such as fever, cough, or diar-
rhea; however, some patients may remain asymp-
tomatic (8,9). As in our cohort, anti-SARS-CoV-2 IgG 
was found in both symptomatic and asymptomat-
ic SOTRs, with significant difference in the VNT 
positivity among patients who reported COVID-19 
related symptoms in the past six months (KTRs - 
fever, cough, anosmia and ageusia; LTRs - cough 
and breathing difficulties) compared to the asymp-
tomatic patients. 
In the context of immunocompromised popula-
tions, such as SOTRs, an open question remains re-
garding the robust antibody response after the 
SARS-CoV-2 infection. In June 2020, a UK study 
demonstrated an anti-SARS-CoV-2 IgG prevalence 
of 10.4% in a large cohort of KTRs. Interestingly, 
33% of patients with prior COVID-19 infection were 
IgG seronegative at a median time of 36 days post-
diagnosis (10). Prendecki et al. tested historical pre- 
and post-COVID-19 samples of 38 KTR, showing 
that all pre-COVID-19 samples were negative while 
68.4%, 92.1%, and 81.6% of post-COVID-19 sam-
ples tested antibody positive using three different 
serological assays. Notably, 7.9% of patients did 
not have detectable antibodies on any assay, rep-
resenting a seroconversion failure (10). 
An American study found that KTRs are capable of 
developing an immune response to SARS-CoV-2 at 
least early on, similar to those observed in the 
general population (11). A recent study showed 
that 51% of adult SOTRs had positive anti-nucle-
ocapsid antibodies at least 7 days after the diag-
nosis of SARS-CoV-2 infection and that KTRs were 
less likely to test positive compared to other 
SOTRs. Transplant-related variables (time after the 
transplant and immunosuppression) were impor-
tant predictors of antibody response to SARS-
CoV-2 infection (12). 
Patients with more severe disease tend towards 
higher antibody levels (9). Similar to the results of 
other studies, our study showed that symptomatic 
patients developed higher NT antibody titers com-
pared to asymptomatic ones. Compared to a pre-
vious Croatian study in the general population, 
the prevalence of NT antibodies was slightly high-
er in the SOTRs (3.1% vs. 2.2%) (6). However, it is im-
portant to note that NT antibodies were detected 
in 15.6% ELISA positive SOTRs compared to 8.3% 
of the general population. The study in the Croa-
tian general population was conducted after the 
first wave, while SOTRs were tested at the begin-
ning of the second wave when the number of 
COVID-19 cases increased sharply which could ex-
plained at least in part the observed difference in 
VNT positivity rates.
It was previously shown that most of the asympto-
matic and mildly ill patients did not produce sig-
nificant levels of IgM antibodies, indicating that 
the IgM diagnosis is not sensitive and efficient. In 
contrast, similar IgG responses were detected in all 
patients (13). Therefore, IgM antibodies were not 
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tested in this study and should be regarded as one 
of the limitations of the study.
In addition, the study’s cross-sectional design pre-
cludes us from drawing conclusions regarding the 
duration of anti-SARS-CoV-2 IgG in SOTRs or distin-
guishing between impaired antibody production 
or a rapid decline, as we lack the data regarding 
the level of the immunosuppression and serial 
time point measurements with longer follow-up.
In immunocompromised patients such as SOTRs, it 
is necessary to understand the immune response 
to SARS-CoV-2 and identify factors associated with 
inadequate antibody response among those who 
failed to seroconvert. Therefore, further studies 
are needed to assess the dynamic of NT antibodies 
and COVID-19 immunity duration in immunocom-
promised populations such as LTRs and KTRs.
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